VCG
IOVA icon

Vantage Consulting Group’s Iovance Biotherapeutics IOVA Stock Holding History

Vantage Consulting Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21
Closed -$1K – 808
2020
Q4 		$1K Buy
+21
New +$834 ﹤0.01% 1763

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vantage Consulting Group's IOVA Position: Q1 2021 in Review

Vantage Consulting Group sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 21 shares — an estimated $1K sold.

Vantage Consulting Group first reported a position in IOVA in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

  • Vantage Consulting Group reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 21 Iovance Biotherapeutics shares in Q1 2021, an estimated $1K.
  • Vantage Consulting Group first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Iovance Biotherapeutics position peaked at $1K in Q4 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.